Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Pfizer and Celltrion Seek Biosimilar Interchangeability for Crohn’s Disease Drug



The Phase III clinical trial – conducted in partnership with Celltrion – found no statistical difference in response rates for patients taking Inflectra (infliximab CT-P13) or Remicade (infliximab).

Share this!

February 27, 2017 | by Sarah Hand, M.Sc.

Pfizer recently reported that its biosimilar version of Johnson and Johnson’s Remicade, showed similar efficacy compared to the reference biologic in patients with moderate-to-severe Crohn’s disease. The Phase III clinical trial – conducted in partnership with Celltrion – found no statistical difference in response rates for patients taking Inflectra (infliximab CT-P13) or Remicade (infliximab).

“Today’s presentation of randomized control trial data in patients with Crohn’s disease further supports the existing clinical profile of CT-P13 in inflammatory bowel disease,” said Dr. Sam Azoulay, Senior Vice President, Chief Medical Officer, Pfizer Essential Health, Pfizer. “In addition to existing data from the registration studies, real-world experience and the NOR-SWITCH trial, this data adds to the body of evidence supporting use of CT-P13 across its approved indications.”

This study is also investigating the safety and efficacy of patients who switched from Remicade to Inflectra, or vice-versa. If those results are similarly positive, the study could support the approval of Inflectra as an interchangeable biosimilar to Remicade.

In January, the FDA released draft guidance on interchangeability requirements for biosimilars, which requires the copycat biologics to demonstrate the same clinical results as their branded counterparts for all indications. To date, none of the few approved biosimilars have met these requirements.

If Pfizer and Celltrion are able to show interchangeability for Inflectra, pharmacies would be able to dispense the less costly drug to patients with a prescription for Remicade. Pharmacists already practice drug substitution when a generic version of a branded pharmaceutical is available.

The randomized, double-blind, parallel-group trial enrolled 214 patients with Crohn’s disease. The primary endpoint was to show that the safety and efficacy of Inflectra was no different to that of Remicade, and this endpoint was met by the end of the sixth week of the 54-week study.

Patients treated with Inflectra saw a 71.4 percent response rate, compared to 75.2 percent for patients given Remicade. The treatment response was measured based on the number of patients who had a minimum 70-point reduction on the Crohn’s Disease Activity Index (CDAI-70).

Pfizer and Celltrion expect further study results to be available later this year. In 2016, Remicade sales hit $6.97 billion; if granted interchangeability, Inflectra has the potential to be a significant competitor in the Crohn’s market.

Keywords: Biosimilar, Biologic, FDA


Share this with your colleagues!

Insurance Coverage Under the Affordable Care Act Supports Clinical Trial Enrollment, Says Study

July 20, 2017 - Since the Patient Protection and Affordable Care Act (ACA) was passed in 2010, insurance approval for patients wishing to participate in oncology clinical trials has increased, according to a recent study published in the journal, Clinical Cancer Research.

Featured In: Clinical Trial News

FDA Approves Puma Biotechnology’s Extended Adjuvant Therapy for Breast

July 19, 2017 - Puma Biotechnology’s breast cancer drug Nerlynx (neratinib) has been approved by the US Food and Drug Administration (FDA).

Featured In: Biotech News

CAR-T Cell Therapy Shows Promise as Leukemia Treatment in Early Stage Clinical Trial

July 19, 2017 - About 70 percent of clinical trial participants with chronic lymphocytic leukemia experienced tumor shrinkage after being treated with CAR-T immunotherapy, according to researchers at Fred Hutchinson Cancer Research Center.

Featured In: Clinical Trial News


Manufacturing Control Strategies: What Pharmaceutical and Biotech Companies Need to Know


Outsourcing Pharmacovigilance: Pros and Cons and Lessons Learned

EDC and eSource: Combined for Better Data and Faster Insights

Using Model Reduction to Bridge the Quality Systems Pharmacology-Pharmacometrics Divide

How to Maximize Your Non-GLP Toxicology Studies: A Guide for Optimal Design and Methodology

Copyright © 2016-2017 Honeycomb Worldwide Inc.